Samuel J. Reich currently serves as Chief Executive Officer of SAB Biotherapeutics. He was elected CEO of SAB BIO in January 2024. Previously, he served as Executive Chairman of SAB’s board of directors following SAB’s business combination with Big Cypress Acquisition Corp in October 2021 until
Eddie J. Sullivan, PhD, is our co-founder and president since 2014. Dr. Sullivan has served in biopharma leadership positions for more than 25 years. Prior to joining us, he held the CEO role or other leadership roles in our predecessor entities, including CEO of Hematech, a subsidiary of Kyowa
Lucy To was named Chief Financial Officer in August of 2024, bringing over 18 years of investment banking and strategic operational expertise to SAB to lead corporate finance, corporate strategy and approach to broader strategic business relationships at the company.
Christoph Bausch, PhD, MBA, is our Chief Operating Officer as of May 2022, overseeing all Research & Manufacturing operations of the company. Prior to his role as COO, he served as Chief Science Officer since joining SAB in April 2017, providing leadership in all areas of Research & Development,
Dr. Kropotova MD, MBA is our Executive Vice President & Chief Medical Officer, joining SAB in June, 2022 to lead the strategy, direction, and execution of the company’s clinical development for the entire portfolio. Dr. Kropotova is a biopharmaceutical executive with expertise in all phases of
Carlos Carrillo, Ph.D., M.Sc., brings more than 29 years of exceptional experience in developing innovative biological and drug products from concept to commercialization, small and large molecules. Dr. Carlos Carrillo has dedicated his career to advancing therapies in diverse areas such as
Mark Conley has served as our Vice President of Finance since November 2023. Prior to joining SAB, Mark was the CFO of Radius Health where he helped transition the commercial bone health business through a major private equity transaction. Mark has extensive experience in driving financial
Catherine DeRose joined SAB BIO in February, 2024 as Vice President of Human Resources and brings to the company extensive Human Resources, Organizational Leadership and Operational experience across various industries, including pharmaceutical manufacturing/packaging, medical devices and consumer
Angie Parizek joined SAB in March 2023 as Vice President, Clinical Operations. Angie leads the planning, execution and oversight of SAB’s global clinical trials. She brings over 25 years of experience in clinical research including clinical trial management, site management, process development and
Todd Stahl serves as the Vice President of Plasma Production at SAB, having worked with Tc Bovine project for over 20 years. Prior to joining SAB in 2014, Todd was the president of Hematech GAC Venture, LLC, a joint venture between Hematech and Trans Ova Genetics, which oversaw the care and
Stan is a physician-scientist with over 25 years of experience in global clinical development, regulatory strategy, and drug development. His work spans rare diseases, immunology, and biologics, with contributions to multiple clinical programs from early-phase trials to post-marketing.
Hua Wu, PhD, serves as the Senior Vice President of Product Development at SAB, bringing over 20 years of extensive experience in the biopharma industry. Since 2014, she has held senior leadership roles at SAB, including Senior Vice President of Research and Product Development.
